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Sllmmary 
To expand the spectrum of recognition of effector lymphocytes and to redirect them towards 
predefined targets, we have altered the specificity of human tumor-infiltrating lymphocytes (TIL) 
through stable modification with chimeric receptor genes consisting of single-chain antibody 
variable regions linked to the 3' subunit common to the immunoglobulin  (Ig)G and IgE Fc receptors. 
Using either hapten or ovarian carcinoma-specific monoclonal antibodies, we constructed chimeric 
receptor genes and retrovirally introduced them into CD8 + TIL. Redirected TIL specifically 
lysed trinitrophenyl-labeled  Daudi or a human ovarian carcinoma cell line (IGROV-1),  and secreted 
granulocyte/macrophage  colony-stimulating  factor upon stimulation with the appropriate antigen. 
This strategy may allow new approaches towards the adoptive immunotherapy  of cancer in humans. 
A  limitation in the use of adoptive cellular immunotherapy 
for cancer  lies in the difficulty in obtaining specific 
tumor-infdtrating  lymphocytes (TIL) for many histologic types 
of cancer. In contrast, many mAbs have been described that 
bind tumor-associated antigens shared by tumors of the same 
histology. Two approaches have been attempted to combine 
the effector function of T cells with the antitumor specificity 
of antibodies. One is destruction of tumor by bispecific anti- 
bodies possessing dual specificity for both the target and the 
immune cell (1, 2). However, the use of bispecific antibodies 
for therapy is limited  by the inaccessibility  of many solid tumors 
to antibody penetration (3) and dissociation of antibody from 
the lymphocyte membrane in a relatively short period of time 
(4). A second approach involves the construction of chimeric 
receptors containing the V regions of antibodies joined to 
the C  regions of the TCR (5-9).  Because antigen binding 
by most antibodies requires both light and heavy V region 
chains (V. and VL), and TCR function requires both oe and 
(or 3//8) chains,  this approach necessitates the coexpres- 
sion of two chimeric genes. While the stable expression of 
multiple genes has been possible in transformed T cells and 
hybridomas, it has been difficult in primary T cells. To over- 
come these problems, we have constructed chimeric receptor 
genes containing VL/V. single-chain V domains (scFv) from 
mAbs linked to the Fc receptor-associated 3, chain (10). The 
scFv, which consists of VL bridged to V. via a flexible linker, 
has been demonstrated to have similar binding affinities and 
specificities compared to natural Fab fragments (11). The 3, 
chain is the signal transdudng subunit of both the high affinity 
IgE receptor (FceRI) of mast cells and basophils,  and of the 
low affinity receptor for IgG (Fc3,RIII), expressed primarily 
by macrophages and NK cells (12). The 3, subunit is very 
similar in structure and function to the CD3~" chain and in 
fact can form heterodimers with it in some T and NK cells 
(13). The scFv-3, design that we have used for the present 
studies combines antibody recognition and T cell signaling 
in one continuous gene, and has been successfully used to 
endow  murine  CTL  hybridoma  cells  with  non-MHC- 
restricted, antibody-type specificity (10). 
Materials and Methods 
Establishment and Maintenance of TIL.  TIL were derived from 
enzymatically  digested tumor biopsies as previously  described  (14). 
Briefly, melanoma tumor biopsies were digested overnight in col- 
lagenase type IV (1/~g/ml), hyaluronidase  (0.1/~g/ml), and DNAse 
(30 U/ml) (Sigma  Chemical Co., St. Louis, MO). After digestion, 
the single-cell  suspensions  were passed  through a sterile wire screen 
grid, and subjected to Ficoll-Hypaque separation to remove dead 
cells and red blood cells. TIL cell cultures were established  at 5.0 
x  10  s cells/ml in 24-well tissue culture plates in RPMI 1640 sup- 
plemented  with 10% human A serum (BioWhittaker, Inc., Walkers- 
ville, MD). This was mixed 1:1 (vol/vol) with AIM V serum-free 
medium (Gibco Laboratories, Grand Island, NY) and was further 
supplemented  with gentamicin-sulfate  (10 #g/ml), penicillin  G so- 
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tories), ID2 (7,200 IU/ml) (Chiton Corp., Emeryville, CA) and 
10% (vol/vol) lymphokine-activated  killer (LAK) cell-conditioned 
supernatant. Since  TIL can double every  2-4 d, TIL densities were 
maintained  at  5  x  10  s  by  splitting  cultures  every 3-5  d 
with fresh medium containing I1.-2 and passaging to larger cell 
culture plates (six well) when required. When TIL reached > 2 
x  10  s in  number,  they were cultured  in  AIM V  serum-free 
medium alone containing 6,000 IU/ml IL-2. Large-scale TIL ex- 
pansion was performed in gas-permeable PL732 3-liter plastic bags 
(Fenwal, Deerfield, IL). 
Construction of Chimeric Genes.  The Sp6 anti-2,4,6 TNP anti- 
body (15, 16) and MOv18 anti-ovarian carcinoma antibody (17, 
18) V. and VL genes were derived by PCR amplifications using 
oligodeoxynucleotide primers corresponding to the 5' and 3' con- 
sensus amino acid sequences of Ig V regions, and joined together 
using a flexible  linker, as described (10), introducing a BstEII site 
at the 3' end of the scFv. Sp6 genomic DNA clones was kindly 
provided by Dr. Georges K6hler (Max Planck Institute for Im- 
munobiology, Freiburg, Germany), and MOv18 genomic DNA 
was kindly provided by Dr. Leslie  Coney (Centocor, Malvern, PA). 
The ~/chain DNA was amplified  from a human cDNA clone (19) 
using primers introducing BstE II and Xho I at the 5' and 3' ends, 
and was then ligated to the scFv via BstE II, to form plasmid 
pRSVscFvR3' (10). 
Retroviral Vectors  and Gem Transfer.  The retroviral LXSN vector 
containing the chimeric receptor ScFv-~/construct  (see Fig. 1) was 
introduced by CaPO4 transfection into the GP+E 86 ecotropic 
packaging cell line (21). 48 h later, supernatant from these cells 
was used to transduce the PA317 amphotropic packaging cell line 
(22). High-titer  G418-resistant PA317 clones were then selected, 
and used for 72-h cocultivation with human melanoma CD8 § 
TIL in the presence of protamine sulfate (5 #g/ml). TIL, which 
grow in suspension, were then separated  by careful pipetting from 
the adherent PA317 cell line. 24-48 h later, TIL were selected for 
5 d in 0.5 mg/ml of  the neomycin  analogue G418 (Geneticin; Gibco 
Laboratories), followed by expansion in AIM V, 10% FCS, and 
II_,2 (6,000 IU/ml) (23). After transduction and G418 selection of 
TIL, Southern and Northern analyses  using V. genomic DNA as 
a probe were performed to confirm successful gene insertion and 
transcriptional expression. 
SlCr Release Cytotoxicity Assay.  TIL were evaluated for their 
ability to lyse specific targets using a standard SlCr release assay 
as previously described (24). After SlCr labeling of targets, TNP 
labeling of cells was performed by addition of a freshly prepared 
10-ram  solution  of  2,4,6-trinitrobenzenesulfonic  acid (Fluka 
Chemika-BioChemika, Buchs, Switzerland) in a 1:1 (vol/vol) ratio 
followed  by a 10-min incubation at 37~  Cells were then washed 
three times in complete medium before use in the cytolysis assay. 
Effectors and targets were cocultured for 4-16 h. The percent spon- 
taneous release for all studies was <30%.  For the lysis inhibition 
studies, a constant E/T ratio of 90:1 was used. 
GM.CSF Assay.  106 TIL and 106 stimulator cells were cocul- 
tured for 24 h at 37~  in a final  volume of 1 ml AIMV/Ib2. Su- 
pernatants were then aspirated, centrifuged at 2,000 rpm to re- 
move cells, decanted, and frozen at - 70~  Thawed aliquots were 
tested in an ELISA for human GM-CSF (Genzyme Corp., Cam- 
bridge, MA). The ELISA used a solid-phase  murine mAb specific 
for human GM-CSF. After addition of either sample or recom- 
binant GM-CSF standard, a rabbit anti-human GM-CSF polyclonal 
antibody was used. A biotin-labeled goat anti-rabbit  polyclonal 
antibody was then added followed by streptavidin-peroxidase. 
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Figure  1.  Schematic  representation  of the scFv-3'  chimeric  receptor  gene 
within the retroviral LXSN backbone. The continuous VL-linker-V,-y 
chain chimeric genes were excised from pRSVscFvR'y (10) with SnaBI 
and XhoI and ligated into the HpaI-XhoI site of LXSN (20), under the 
transcriptional regulation of the Motoney  murine leukemia virus LTR. 
The neomycin  phosphotransferase  gene (mo  O is under the transcriptional 
control of the SV-40 early region promoter. 
Results 
So far, studies reporting antibody/TCR chimeras have used 
antihapten antibodies. For our studies using the scFv-3' de- 
sign, we not only used an anti-TNP mAb (Sp6; 15, 16), but 
also a mAb (MOv18) against the 38-kD folate binding pro- 
tein, a surface antigen present on most ovarian carcinomas 
(17, 18). To obtain stable gene transfer into primary human 
lymphocytes, we used retroviral transduction, which we have 
previously shown to be effective in generating stable, gene- 
modified lymphocytes (25). As an effector cell in our studies, 
we used a human CD8 + melanoma-derived TIL (24). This 
TIL is capable of specifically lysing its autologous melanoma 
target. 
Initially, anti-TNP scFv-'g transduced TIL (Sp-q/) were ex- 
amined to determine if they expressed functional receptors. 
Sp-3' TIL could lyse TNP labeled Dandi, a Burkitt's lym- 
phoma cell line,  but could not lyse unlabeled Daudi,  in a 
standard 51Cr release assay (24) (Fig.  2 A). Nontransduced 
TIL (NV) and TIL transduced with a chimeric receptor of 
another specificity (MOv-3') could lyse neither TNP-labeled 
nor unlabeled Daudi. Similar results were obtained with a 
TNP-labeled EBV-transformed B cell line as a target. Per- 
cent specific lysis against TNP-labeled EBV-B cells was 39 
and 9%  when using either SP-3' TIL or NV TIL, respec- 
tively,  at equivalent E/T values in a 4-h standard SlCr re- 
lease assay. Under similar conditions, no lysis of unlabeled 
EBV-B cells was observed by either TIL line.  Lysis against 
TNP-labeled cells by Sp-3' TIL was specific for TNP,  and 
was blocked by soluble TNP fowl gamma globulin (Fig. 2 B). 
We next examined whether this approach could be used 
to specifically redirect lymphocytes against tumor. A chimeric 
receptor  (MOv-30  was  constructed  using  an  scFv  from 
MOv18, a mAb that is relatively specific for human ovarian 
carcinoma. The same TIL were retrovirally transduced with 
the chimeric MOv-3' receptor and selected in G418. The MOv- 
"y-modified TIL (MOv-3, TIL) lysed IGROV-1 cells, a human 
ovarian carcinoma cell line that expresses high levels of the 
38-kD folate binding protein recognized by MOv18 (26, 27) 
(Fig. 3 A). However, neither nontransduced TIL nor the TNP- 
specific Sp-y TIL could lyse IGROV-1. Lysis of IGROV-1 
by MOv-3' TIL was specific for the MOvlS-defined protein, 
and was blocked by anti-MOv18 idiotypic antibody (28) in 
a dose-dependent fashion (Fig. 3 B). In addition, specific lysis 
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Figure  2.  Anti-TNP Sp-  7  TIL 
are  redirected  to  specifically  lyse 
TNP-labeled  targets. (.4)  Lysis of 
autologous melanoma  and  TNP- 
unlabeled and labeled Daudi cells. 
Only  the  Sp-7  TIL,  transduced 
with the chimeric svFv-'y gene de- 
rived from the anti-TNP mAb Sp6, 
lyse the TNP-labeled Dandi, while 
nontransduced and MOv-'y TIL do 
not. (B) Lysis  of TNP-labeled Daudi 
by Sp-'y TIL is inhibited by soluble 
TNP-fowl gamma globulin (F'yG) 
but not by unlabeled F'yG in a dose- 
dependent  fashion.  TIt  were  in- 
cubated with either FTG or TNP- 
FTG for 2 h before the addition of 
SlCr-labeled targets. Lysis of auto- 
logous melanoma was used as a spe- 
cificity control, and was not affected 
by either soluble TNP-FTG or un- 
labeled FTG (not shown). 
by Sp-'y and MOv-'y TIL for their respective targets was stable 
on serial assays over a 33-d  period  (not shown). 
To further study the specificity of MOv-'y and Sp-7 TIt, 
lysis was tested against multiple targets. The IGROV-1 cell 
line and the TNP-labeled Daudi cell line were specifically lysed 
by the MOv-7 and Sp-7 TIL, respectively. Since the TIL 
used were derived from melanoma, all groups were able to 
lyse the autologous melanoma, but were unable to lyse al- 
logeneic melanoma, breast, or unmodified Daudi cell lines. 
FACS  ~ analysis using the MOvl8 antibody demonstrated that, 
indeed, only the IGROV-1 cell line expressed significant levels 
of the MOv18-defined  protein  (not shown). 
To  additionally  evaluate the  function of the Sp-'y and 
MOv-'y receptors in TIL, we examined their ability to mediate 
GM-CSF secretion after receptor activation by cocultivation 
with different stimulator cells (Table 1). Sp-'y TIt specifically 
secreted GM-CSF after stimulation by TNP-labeled EBV- 
transformed B cells and Daudi cells, but not after stimula- 
tion by unlabeled cells. Likewise, only IGROV-1 cells stimu- 
lated specific GM-CSF secretion by MOv-7 TIt. 
Discussion 
This study demonstrates that primary CD8 + T cells can 
be stably modified genetically  to be redirected against new 
antigens, defined by mAbs. Thus far, studies using chimeric 
antibody/TCRs have used antihapten antibodies, wherein the 
V. by itself could account for most of the antigen binding 
(5-9).  Here we report for the first time a chimeric scFv-  7 
receptor made of a mAb specific for a more complex protein 
antigen.  Apparently, both V. and Vr of MOv18 are needed 
to bind antigen,  since the MOv18 V.Ca chimeric receptor 
did not confer antibody specificity after transduction into TIt 
(not shown), in contrast to the reactivity conferred by the 
anti-TNP (Sp6) V.C~ receptor (8). The present work com- 
plements recent studies in which chimeras of the 3' or ~'chain 
joined to extracellular CD4, CD8, IL-2 receptor, and CD16 
domains could be functionally expressed in transformed T 
lymphocytes  and basophils (29-31). Here we have extended 
this work to include single-chain antibody variable fragments 
as the extracellular ligand binding domains  (10).  We have 
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Figure  3.  The  human  ovarian 
carcinoma  cell  line  IGKOV-1  is 
specifically lysed by MOv-'y TIL. 
(.4)  Lysis of IGKOV-1. Only the 
MOv-7  TIL,  transduced with  a 
chimeric receptor gene derived from 
the MOv18 antibody, lyse IGROV-1, 
while nontransduced and Sp-7 TIL 
do  not.  (/3) Lysis of  IGROV-1 
by  MOv-7  TIt  is  inhibited  by 
anti-MOv18 idiotype antibody in a 
dose-dependent fashion. TIL were 
incubated with either anti-MOv18 
idiotype antibody or an irrelevant 
antibody,  anti-Sp6  idiotype  anti- 
body, for 2 h before the addition of 
slCr-labeled targets. Lysis of autol- 
ogous melanoma was studied as a 
control, and was not effected by ei- 
ther  anti-idiotype  antibody  (not 
shown). 
363  Hwu et al.  Brief Definitive Report Table  1.  GM-CSF Secretion by SP-  7  and MOv-  7  TIL after Antigen Stimulation 
GM-CSF production 
EBV-B cell  Daudi 
Exp.  TIL  None  No TNP  +  TNP  No TNP  +  TNP  IGROV-1 
pg/ml/lO  a TIL/24  h 
Nontransduced  8  27  43  27  28  7 
Sp-3'  13  52  )512  73  ~512  4 
MOv-3,  22  38  62  36  40  269 
Nontransduced  24  63  130  45  32  37 
Sp-3'  17  62  493  38  152  25 
MOv-3,  6  47  81  35  34  165 
106 TIL were cocultured with  106 stimulators in a final volume of 1 ml AIM V medium (containing 6,000 IU/ml IL-2). After a 24-h incubation 
at 37~  supernatants were harvested and cells were removed by centrifugation. Supematants were stored at  - 70~  before GM-CSF ELISA (Gen- 
zyme Corp.). 
used the 3, subunit of the Fc receptor to transduce the signal 
from ligand binding as well as to anchor the scFv receptor 
to the plasma membrane. However, other transmembrane/cy- 
toplasmic signaling molecules that trigger cell activation or 
proliferation could potentially be used, such as the CD3- 
associated ~'chain (10), TCR c~ or/3 chains, or the IL-2 receptor 
a,/3,  or 7  chains. 
As our effector cell, we have chosen a primary human T 
lymphocyte that could be used for immunotherapy, rather 
than transformed cell lines used in previous studies. In these 
redirected TIL, the chimeric receptor mediated both specific 
cytolysis against tumor as well as cytokine release, both of 
which have been implicated in the antitumor effects of TIL 
(32, 33). Although we have used TIL in this study, alterna- 
tive effector cells, such as OKT3-stimulated PBL, NK cells, 
and CD4 + T calls could potentially be used. We have used 
retroviral-directed gene modification, as opposed to transient 
methods of lymphocyte gene transfer,  such as recombinant 
vaccinia virus infection.  Retroviral  transduction has  been 
shown to be capable  of stably  introducing foreign genes 
without adversely affecting lymphocyte function over time 
(25),  and indeed the chimeric receptors were functional in 
TIL by serial studies over a 33-d period. In fact, TIL trans- 
duced retrovirally with a neomycin phosphotransferase marker 
gene have been safely infused into patients receiving im- 
munotherapy for metastatic melanoma (34). Therefore, eff~or 
T cells redirected by retroviral modification with the chimeric 
receptor described here could potentially be used for adop- 
tive immunotherapy in cancer patients. 
In this study, we have conferred on TIL antitumor specifidty 
using the MOv18 antibody directed against ovarian carcinoma. 
However, mAbs directed against many different tumor histol- 
ogies are available, and can serve to generate chimeric receptors 
against other histologies, including breast,  colon, prostate, 
and lung cancer. In addition, antiviral mAbs could be used 
to redirect lymphocytes against vitally infected cells. Of note, 
the adoptive cellular immunotherapy of viral infections was 
recently demonstrated to be of potential benefit for cytomeg- 
alovirus  prophylaxis in the setting of bone marrow trans- 
plantation (35). Therefore, the stable, genetic modification 
of primary T cells with chimeric receptors containing single- 
chain antibody V regions, as described here, has the poten- 
tial to extend the current scope of antitumor adoptive cel- 
lular immunotherapy to include multiple additional cancer 
histologies, and, in addition, could broaden the immuno- 
therapy of viral infections such as HIV and hepatitis B without 
the  cumbersome process  of isolating naturally  occurring 
specific immune T  cells. 
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